SAN FRANCISCO, Aug. 1 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals,
Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of
compounds for the treatment of cardiovascular disease, announced today that
Rebecca A. Taub, MD, VIA's senior vice president of research and
development, will present at the 13th Annual IBC Life Sciences Drug
Discovery & Development of Innovative Therapeutics World Congress taking
place August 4-7 in Boston, MA.
The presentation details are as follows:
Date/Time: Wednesday, August 6, 2008: 2:20-2:50 p.m. ET
Location: World Trade Center Boston & Seaport Hotel
Session: Translational Medicine IV: Case Studies of Translational
Approaches from Preclinical to Clinical Proof-of-Concept
Title: Innovative Clinical Trial and Biomarker Approaches To Demonstrate
the Role Of Leukotrienes and 5LO Inhibition in Atherosclerotic Disease
"VIA has taken an innovative approach in its design of Phase 2 clinical trials for VIA-2291, its lead compound," said Dr. Taub. "I am excited to share with conference participants our view on the value of innovative techniques in the design of critical clinical trials, particularly with regards to serum inflammatory biomarkers, analyses of atherosclerotic plaque tissue, and non-invasive imaging."
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.
|SOURCE VIA Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved